Correlation of laboratory and clinical data during treatment of leprosy.
D000814:Aniline Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use; D003622:Dapsone / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D007097:Imines / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000302:isolation & purification; D010619:Phenazines / Q000009:adverse effects / Q000627:therapeutic use; D010859:Pigmentation Disorders / Q000139:chemically induced; D012293:Rifampin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
D000814:Aniline Compounds; D000962:Antimalarials; D007097:Imines; D010619:Phenazines; D013449:Sulfonamides; D003622:Dapsone; D012293:Rifampin